3 Note that this consensus algorithm is a guide and that the clinical management of T2DM should always incorporate the patients unique goals, comorbidities, individual response to therapy, and other factors that may introduce unwanted drug interactions or contraindications to a particular therapy or therapies
GLP-1 users come to these drugs for a variety of reasons
The Beneficiaries of GLP-1 Drugs Across Industries Health Insurers and the Cost of Obesity Source: McKinsey 4 Although weight loss has been the main focus in the analyses of these drugs so far, it is important to bear in mind that with them comes the improvement in other measurements of health, such as blood glucose levels, cardiovascular parameters, cholesterol and triglyceride levels
Orforglipron Compared With Dapagliflozin in Adults With Type 2 Diabetes and Inadequate Glycaemic Control With Metformin (ACHIEVE-2): A Multicentre, Randomised, Non-Inferiority, Open-Label, Phase 3 Trial